Search Within

Linda Su Hyun Ahn

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Journal Article (11)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (13)
  2. Department of Pathology and Laboratory Medicine (13)
  3. Nursing (13)
  4. Solid Tumor Oncology Division (13)
  5. GSK Faculty (11)
  6. Tow Center for Developmental Oncology (TCDO) (10)

More Groups

People
  1. Mark Kris (8)
  2. Helena Yu (6)
  3. Gregory Riely (5)
  4. Marc Ladanyi (5)
  5. Cristina Antonescu (4)
  6. Mary Keohan (4)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (2)
  4. 2021 (1)
  5. 2020 (1)
  6. 2019 (2)

More Years

Publications
  1. Clinical Cancer Research (2)
  2. Journal of Clinical Oncology (2)
  3. Cancer (1)
  4. Cold Spring Harbor Molecular Case Studies (1)
  5. JAMA Oncology (1)
  6. JCO Precision Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (3)
  2. American Association for Cancer Research (2)
  3. American Medical Association (1)
  4. Cold Spring Harbor Laboratory Press (1)
  5. Elsevier BV (1)
  6. Elsevier Inc. (1)

More Publishers

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations
    Meeting Abstract

    Chen, M. F.; Rakhade, S.; Quintanal-Villalonga, A.; Lee, J.; Forsythe, B.; Moses, K. A.; Ahn, L. S. H.; Pupo, A.; Falcon, C. J.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Journal Article

    Paik, P. K.; Fan, P. D.; Qeriqi, B.; Namakydoust, A.; Daly, B.; Ahn, L.; Kim, R.; Plodkowski, A.; Ni, A.; Chang, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas
    Journal Article

    Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas
    Journal Article

    Paik, P. K.; Luo, J.; Ai, N.; Kim, R.; Ahn, L.; Biswas, A.; Coker, C.; Ma, W.; Wong, P.; Buonocore, D. J.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Phase 1 clinical trial of trametinib and ponatinib in patients with NSCLC harboring KRAS mutations
    Journal Article

    Arbour, K. C.; Manchado, E.; Bott, M. J.; Ahn, L.; Tobi, Y.; Ni, A. A.; Yu, H. A.; Shannon, A.; Ladanyi, M.; Perron, V.; more...
    JTO Clinical and Research Reports (2022)

    Fulltext@MSK | Save
  • Erlotinib and trametinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to a prior tyrosine kinase inhibitor
    Journal Article

    Luo, J.; Makhnin, A.; Tobi, Y.; Ahn, L.; Hayes, S. A.; Iqbal, A.; Ng, K.; Arcila, M. E.; Riely, G. J.; Kris, M. G.; more...
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save
  • Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial
    Journal Article

    Yu, H. A.; Schoenfeld, A. J.; Makhnin, A.; Kim, R.; Rizvi, H.; Tsui, D.; Falcon, C.; Houck-Loomis, B.; Meng, F.; Yang, J. L.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • A phase II trial of sorafenib and dacarbazine for leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumors
    Journal Article

    D'Adamo, D. R.; Dickson, M. A.; Keohan, M. L.; Carvajal, R. D.; Hensley, M. L.; Hirst, C. M.; Ezeoke, M. O.; Ahn, L.; Qin, L. X.; Antonescu, C. R.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Exceptional responders with invasive mucinous adenocarcinomas: A phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
    Journal Article

    Drilon, A.; Schoenfeld, A. J.; Arbour, K. C.; Litvak, A.; Ni, A.; Montecalvo, J.; Yu, H. A.; Panora, E.; Ahn, L.; Kennedy, M.; more...
    Cold Spring Harbor Molecular Case Studies (2019)

    Fulltext@MSK | Save
  • Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas
    Journal Article

    Schilsky, J. B.; Ni, A.; Ahn, L.; Datta, S.; Travis, W. D.; Kris, M. G.; Chaft, J. E.; Rekhtman, N.; Hellmann, M. D.
    Lung Cancer (2017)

    Fulltext@MSK | Save